Clinical trial
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
NCT00064220 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00064220 |
|---|---|
| Title | Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma |
| Official title | A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy |
| Lead sponsor | Daiichi Sankyo, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | soblidotin |
| Start date | Apr 1, 2003 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Jul 9, 2003 |
| Last update posted | May 16, 2012 |
| Countries | Puerto Rico, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: